Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-967P designates a sequence classified as a pseudogene within the U6 small nuclear RNA family. U6 snRNA is a crucial component of the spliceosome complex in eukaryotic cells, facilitating mRNA splicing[5]. Pseudogenes such as RNU6-967P arise from duplication or mutation events and lack the ability to encode functional RNA products[1]. There is no evidence that RNU6-967P is expressed, functional, or involved in any biological or disease process. It should be distinguished from the active U6 snRNA gene, which is evolutionarily conserved and essential for cell viability[5]. No interaction with drugs, role as a biomarker, or disease association is described in any current database or publication. Therefore, RNU6-967P is not considered a molecular target for therapeutic intervention[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 967, pseudogene (RNU6-967P).